Guoxun Li

Guoxun Li

Auto-generated profile, based on publicly available information

Guoxun Li

School of Pharmacy, Changzhou University, Changzhou, Jiangsu 213164, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 August 2021 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
ZLZiyao Li
Ziyao Li
SLShaofei Li
Shaofei Li
HTHangbo Tao
Hangbo Tao
YZYixiang Zhan
Yixiang Zhan
KNKemin Ni
Kemin Ni
GLGuoxun Li
Guoxun Li
Background: There have been controversial voices on if hepatitis B virus infection decreases the risk of colorectal liver metastases or not. This study aims to the find the association between HBV infection and postoperative survival of colorectal cancer and the risk of liver metastases in colorectal cancer patients. Methods: Patients who underwent curative surgical resection for colorectal cancer between January 2011 and December 2012 were included. Patients were grouped according to anti-HBc. Differences in overall survival, time to progress, and hepatic metastasis-free survival between groups and significant predictors were analyzed. Results: Three hundred twenty-seven colorectal cancer patients were comprised of 202 anti-HBc negative cases and 125 anti-HBc positive cases, and anti-HBc positive cases were further divided into high-titer anti-HBc group (39) and low-titer anti-HBc group (86). The high-titer anti-HBc group had significantly worse overall survival (5-Yr, 65.45% vs. 80.06%; P < .001), time to progress (5-Yr, 44.26% vs. 84.73%; P < .001), and hepatic metastasis-free survival (5-Yr, 82.44% vs. 94.58%; P = .029) than the low-titer group. Multivariate model showed anti-HBc ≥ 8.8 S/CO was correlated with poor overall survival (HR, 3.510; 95% CI, 1.718–7.17; P < .001), time to progress (HR, 5.747; 95% CI, 2.789–11.842; P < .001), and hepatic metastasis-free survival (HR, 3.754; 95% CI, 1.054–13.369; P = .041) in the anti-HBc positive cases. Conclusions: Higher titer anti-HBc predicts a potential higher risk of liver metastases and a worse survival in anti-HBc positive colorectal cancer patients.

5 August 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
GLGuoxun Li
Guoxun Li
XFXiaoqing Feng
Xiaoqing Feng
WWWenqian Wang
Wenqian Wang
JLJian Li
Jian Li
YSYeye Shi
Yeye Shi
CHcaijuan Hu
caijuan Hu

30 March 2021 in Research Square
Verified
Preprint
Open access
PDF file
ZLZiyao Li
Ziyao Li
SLShaofei Li
Shaofei Li
HTHangbo Tao
Hangbo Tao
YZYixiang Zhan
Yixiang Zhan
KNKemin Ni
Kemin Ni
GLGuoxun Li
Guoxun Li
Purpose: This study aims to the find the association between HBV infection and postoperative survival and the risk of liver metastasis in colorectal cancer patients.Methods: Patients who underwent curative surgical resection for colorectal cancer (CRC) between January 2011 and December 2012 were included. Patients were grouped according to anti-HBc. Differences in overall survival (OS), time to progress (TTP) and hepatic metastasis-free survival (HMFS) between groups and significant predictors were analyzed.Results: 327 colorectal cancer patients are comprised of 202 anti-HBc negative cases and 125 anti-HBc positive cases, and anti-HBc positive cases are further divided into high-titer anti-HBc group (39) and low-titer anti-HBc group (86). High-titer anti-HBc group had significantly worse overall survival (5-Yr, 65.45% vs. 80.06%; P < .001), time to progress (5-Yr, 44.26% vs. 84.73%; P < .001) and hepatic metastasis-free survival (5-Yr, 82.44% vs. 94.58%; P = .029) than low-titer group. Multivariate model showed anti-HBc ≥ 8.8 S/CO was correlated with poor overall survival (HR, 3.510; 95% CI, 1.718-7.17; P < .001), time to progress (HR, 5.747; 95% CI, 2.789-11.842; P < .001) and hepatic metastasis-free survival (HR, 3.754; 95% CI, 1.054-13.369; P = .041) in the anti-HBc positive cases.Conclusion: Higher titer anti-HBc predicts a higher risk of liver metastasis and a worse survival in anti-HBc positive colorectal cancer patients.